Locations:
Search IconSearch
November 7, 2017/Pulmonary/Research

The Role of the Extracellular Matrix in Asthma Severity

Hyaluronan and heavy chains

17-PUL-3682-Aronica-Hero-Image-650x450pxl

By Mark Aronica, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Despite our increased understanding of the pathobiology of airways inflammation and the development of biologics as a therapeutic tool in the treatment of severe asthma, we still have much to learn regarding the movement of inflammatory cells within the lung and the long-term consequences of chronic inflammation within the lung. Part of the answer may lie in the extracellular matrix.

Much of our understanding of inflammatory cell movement is based on the established roles of selectins, integrins and chemokines in trafficking cells from blood vessels to sites of inflammation. Though we know how these cells are moved, we don’t fully understand what happens when they do.

Hyaluronan: more than just goo

Hyaluronan (HA) is a glucosaminoglycan in which the disaccharide (glucuronic acid-beta-1,3-N-acetylglucosamine-beta-1,4-) is repeated several thousand times. HA is a major constituent of the extracellular matrix. Due to its very simple composition, physical properties and near ubiquitous distribution, for many years HA was considered to be inert scaffolding, having only a mechanical role in supporting and maintaining tissue structure — essentially a goo. However, findings over the last decade indicate that the role of HA is much broader than previously thought.

HA was first noted in the secretions of asthmatics in 1978, and HA levels in the bronchoalveolar lavage (BAL) of asthmatics have since been associated with severity of disease. Additionally, HA can be covalently modified during inflammation with the heavy chains (HCs) of inter-alpha-inhibitor (IαI) to form an HC-HA complex. We and others have shown that HC substitution of HA significantly increases leukocyte adhesion to HA, thereby potentially defining a mechanism through which HC-HA could direct inflammatory events in the asthmatic lung.

Advertisement

Our group’s research has revealed the importance of HA in inflammation and provided strong evidence for HA’s major role in providing the preliminary matrix necessary for collagen synthesis and fibrosis noted in asthmatic airways. We have shown that HA deposition is an early event in the lung, with detectable levels within 12 hours of the first antigen exposure. Our data also reveal that inflammatory cells colocalize in areas of HA deposition, suggesting a role for HA in maintaining and localizing inflammatory cells to sites of danger.

Translating the data to human asthma

Although we completed much of this work in murine models of asthma, we also wanted to confirm that these findings and pathways are present in human asthma. We used immunofluorescent microscopy to examine the distribution of leukocytes within HC-HA matrices in lung tissue from three patients with acute severe asthma. (Figure). The airways of these patients displayed significant smooth muscle proliferation, epithelial metaplasia, mucus gland hypertrophy and airway obstruction due to mucus plugging (E,F). HA was distributed throughout the submucosa region and distributed around, but not within, serous mucus glands (A). Furthermore, HA was largely absent within the mucus of the airway lumen. IαI (i.e., HC) distribution was almost exclusively present in the submucosa region, displaying a striking colocalization with HA indicative of pathological HC-HA matrices (B). Using the common leukocyte antigen CD45 as a generic marker of inflammatory cells, we found large numbers of leukocytes in the submucosa region of these lungs colocalizing with and embedded within pathological HC-HA matrices.

Advertisement

Colocalization of leukocytes within HA matrices modified with heavy chains in asthmatic airways. A paraffin lung section of a patient with acute severe asthma was probed with a hyaluronan binding protein (green; A), an antibody against IαI (red; panel B) and the common leukocyte antigen CD45 (panel C; magenta). DAPI stained nuclei are shown in blue. Overlay is shown in panel D. H&E and trichrome staining from the same region shown in panels A-D are shown in panels E and F, respectively. Magnification is 10x. A magnification bar is portrayed as a white line in panel A (150 μm). The airway epithelium is identified by an E, airway smooth muscle by SM, submucosal glands by G and a mucus plug by an asterisk in panels A-D. These images were representative of three asthmatic replicates. Figure and legend originally appeared in J Biol Chem. 2015;290(38):23124-34. © American Society for Biochemistry and Molecular Biology.]

In summary, we believe that the extracellular matrix, an often ignored component in many diseases, is an active and direct participant in inflammatory processes including asthma, and a better understanding of these mechanisms may lead not only to insights into these processes but also to novel treatment pathways.

Dr. Aronica is staff in the departments of Pulmonary Medicine, Allergy and Clinical Immunology, and Pathobiology

Advertisement

Related Articles

Patient sleeping
August 7, 2024/Pulmonary/Research
Nocturnal Hypoxemia Linked to Muscle Wasting in COPD Patients

Findings show profound muscle loss variance between men and women

Clostridioides difficile bacteria
May 28, 2024/Pulmonary/Research
New Study Points to Feasibility of Breath-Based Diagnostic Test for C. diff

VOC analysis could provide biological insight into risk factors associated with CDI

Man wearing CPAP machine
April 2, 2024/Pulmonary/Research
Treatments for Obstructive Sleep Apnea: CPAP and Beyond

A review of conservative, pressure-based and surgical treatments for OSA

Image of lungs
February 28, 2024/Pulmonary/Research
New Cleveland Clinic-Led Research Highlights Novel Disease Monitoring Technique in Heart Failure

Volatile organic compounds have potential in heart failure diagnostics

24-PUL-4507382-CQD-Portopulmonary-Hypertension-Hero-967×544
January 26, 2024/Pulmonary/Research
Portopulmonary Hypertension: A Focused Review for the Internist

Insights for diagnosing, assessing and treating

opioids
December 6, 2023/Pulmonary/Research
Can Kappa and Alpha-2 Agonist Agents Treat Opioid-Induced Ventilatory Depression Risk While Preserving Analgesic Effects?

Two NIH grants are looking at developing new antidotes against fentanyl overdose

Lab research
November 22, 2023/Pulmonary/Research
Unravelling the Mysteries of Sepsis and Septic Shock

Exploring the responses to medications and other supportive therapies

spirometry
August 7, 2023/Pulmonary/Research
A Tool to Help in Transition to “Race-Neutral” PFT Interpretation

A set of graphs helps quantify the expected changes in forced expiratory volume at one second (FEV1), forced vital capacity (FVC) and FEV1/FVC ratio with the new race-neutral equation

Ad